盐酸安罗替尼联合化疗对宫颈癌患者癌组织血管新生能力及MEK/ERK通路的影响  

Effect of anlotinib hydrochloride combined with chemotherapy on neovascularization capacity and MEK/ERK pathway in patients with cervical cancer

作　　者：徐睿哲 赵培峰[1] Xu Rui-zhe;Zhao Pei-feng(Department of Radiotherapy,the Second Affiliated Hospital of Suzhou University,General Hospital of Nuclear Industry,Suzhou 215000,China)

机构地区：[1]苏州大学附属第二医院(核工业总医院)放疗科,苏州215000

出　　处：《中国药物应用与监测》2024年第2期102-105,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的研究盐酸安罗替尼联合化疗对宫颈癌患者癌组织血管新生能力及MEK/ERK通路的影响。方法选取苏州大学附属第二医院2020年8月—2022年8月收治的68例宫颈癌患者为研究对象,采用随机数字表法分为试验组(n=34)和对照组(n=34)。对照组接受常规化疗治疗,试验组在此基础上联合安罗替尼抗血管生成治疗。对比两组患者临床疗效,治疗前后血管新生能力[血管内皮生长因子(VEGF)、肿瘤微血管密度(MVD)],治疗后MEK/ERK通路分子水平。结果与对照组总有效率58.82%(20/34)相比,试验组88.23%(30/34)更高(χ^(2)=7.555,P<0.05);治疗后,两组患者VEGF、MVD水平均降低,且相比于对照组,试验组更低[对照组分别为(63.98±5.14)ng·g^(-1)、(13.02±1.65)个·mm^(-2),试验组分别为(48.06±5.35)ng·g^(-1)、(6.68±1.62)个·mm^(-2)](t=12.512、15.987,均P<0.05);与对照组患者相比,试验组患者MEK1、MEK2以及ERK1/2水平更低[对照组分别为(2.06±0.19)ng·mL^(-1)、(2.28±0.14)ng·mL^(-1)、(1.48±0.12)ng·mL^(-1),试验组分别为(1.23±0.21)ng·mL^(-1)、(1.06±0.15)ng·mL^(-1)、(0.84±0.11)ng·mL^(-1)](t=17.089、34.670、22.924,均P<0.05)。结论盐酸安罗替尼联合化疗能够有效抑制宫颈癌患者癌组织血管新生能力以及MEK/ERK通路分子水平,临床疗效较高。Objective To investigate the effects of anlotinib hydrochloride combined with chemotherapy on the neovascularization capacity and mitogen-activated protein kinase(MEK)/extracellular signal-regulated kinase(ERK)pathway in patients with cervical cancer.Methods Sixty-eight cervical cancer patients admitted to our hospital from August 2020 to August 2022 were selected,and assigned into two groups using the method of random number table methods,with 34 in each.The control group was given routine chemotherapy,the experimental group added anlotinib based on the control group.The clinical efficacy,neovascularization capacity[vascular endothelial growth factor(VEGF),microvessel density(MVD)],and expression of MEK/ERK pathway related proteins were compared between the 2 groups.Results The experimental group reported a higher clinical efficacy rate as compared with the control[88.23%(30/34)vs.58.82%(20/34),χ^(2)=7.555,P<0.05].A reduction in VEGF and MVD was observed in all patients after treatment,and the reduction was more notable in the experimental group than in the control[(63.98±5.14)ng·g^(-1)vs.(48.06±5.35)ng·g^(-1),(13.02±1.65)capillaries·mm^(-2) vs(6.68±1.62)capillaries·mm^(-2),t=12.512,15.987,all P<0.05].The expression of MEK1,MEK2 and ERK1/2 was down-regulated in the experimental group as compared with the control[(1.23±0.21)ng·mL^(-1)vs(2.06±0.19)ng·mL^(-1),(1.06±0.15)ng·mL^(-1)vs(2.28±0.14)ng·mL^(-1),(0.84±0.11)ng·mL^(-1)vs(1.48±0.12)ng·mL^(-1),t=17.089,34.670,22.924,all P<0.05].Conclusion Application of anlotinib hydrochloride combined with chemotherapy can effectively inhibit the neovascularization capacity and down-regulate the expression of MEK/ERK pathway related proteins in patients with cervical cancer.

关 键 词：宫颈癌 安罗替尼 化疗 血管新生能力 MEK/ERK通路 

分 类 号：R737.33[医药卫生—肿瘤]